Skip to main content
Premium Trial:

Request an Annual Quote

Clarient Licenses HDC's Prostate Cancer Marker for Dx Commercialization

NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
 
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
 
Clarient said the four-gene test could enable early detection of prostate cancer and help doctors make better informed decisions about treatment strategies.
 
Clarient said it plans to immediately start validation programs and then push the test into clinical studies and toward regulatory submission.
 
HDC CEO Stephen Barnhill estimated that the current market for prostate cancer screening is more than $350 million per year and presents a “tremendous market opportunity” for the firm.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.